Member of the Association of American Physicians
Steven E. Nissen mainly investigates Internal medicine, Cardiology, Intravascular ultrasound, Coronary artery disease and Surgery. Many of his studies involve connections with topics such as Placebo and Internal medicine. His work carried out in the field of Cardiology brings together such families of science as Blood pressure and Vascular disease.
The Intravascular ultrasound study combines topics in areas such as Lesion, Lumen, Transplantation and Surrogate endpoint. His studies deal with areas such as Pravastatin and C-reactive protein as well as Coronary artery disease. His Surgery study combines topics from a wide range of disciplines, such as Acute coronary syndrome, Weight loss and Type 2 diabetes.
Steven E. Nissen focuses on Internal medicine, Cardiology, Intravascular ultrasound, Coronary artery disease and Radiology. In his study, Surgery is inextricably linked to Diabetes mellitus, which falls within the broad field of Internal medicine. His research integrates issues of Blood pressure and Cholesterol in his study of Cardiology.
His Intravascular ultrasound research integrates issues from Coronary arteries, Vascular disease, Rosuvastatin, Lumen and Transplantation. As a member of one scientific family, Steven E. Nissen mostly works in the field of Coronary artery disease, focusing on Atorvastatin and, on occasion, Pravastatin. His study in Angiography and Ultrasound is carried out as part of his Radiology studies.
His primary areas of study are Internal medicine, Cardiology, Diabetes mellitus, Coronary artery disease and Randomized controlled trial. His research on Internal medicine often connects related topics like Placebo. His Cardiology research is multidisciplinary, incorporating perspectives in Evolocumab and Lipoprotein.
His Diabetes mellitus research is multidisciplinary, relying on both Obesity and Surgery. His Myocardial infarction research incorporates themes from Stroke, C-reactive protein and Hazard ratio. His work on Glycated hemoglobin as part of general Type 2 diabetes research is often related to Sleeve gastrectomy and Alogliptin, thus linking different fields of science.
His scientific interests lie mostly in Internal medicine, Cardiology, Randomized controlled trial, Placebo and Hazard ratio. Much of his study explores Internal medicine relationship to Gastroenterology. His work on Coronary artery disease, Atheroma and Myocardial infarction as part of general Cardiology research is frequently linked to Free zone, bridging the gap between disciplines.
In his work, Coronary atherosclerosis is strongly intertwined with Lipoprotein, which is a subfield of Coronary artery disease. His Placebo research incorporates elements of Tolerability and Endocrinology. His Hazard ratio study incorporates themes from Surgery and Mace.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Steven E. Nissen;Kathy Wolski.
The New England Journal of Medicine (2007)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso;Gilbert H. Daniels;Kirstine Brown-Frandsen;Peter Kristensen.
The New England Journal of Medicine (2016)
Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis A Randomized Controlled Trial
Steven E. Nissen;E. Murat Tuzcu;Paul Schoenhagen;B. Greg Brown.
American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
Gary S Mintz;Steven E Nissen;William D Anderson;Steven R Bailey.
Journal of the American College of Cardiology (2001)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Steven E. Nissen;Stephen J. Nicholls;Ilke Sipahi;Peter Libby.
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White;Christopher P. Cannon;Simon R. Heller;Steven E. Nissen.
The New England Journal of Medicine (2013)
Risk of cardiovascular events associated with selective COX-2 inhibitors.
D Mukherjee;S.E Nissen;E.J Topol.
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.
Steven E. Nissen;Taro Tsunoda;E. Murat Tuzcu;Paul Schoenhagen.
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Philip R. Schauer;Deepak L. Bhatt;John P. Kirwan;Kathy Wolski.
The New England Journal of Medicine (2017)
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
Steven E. Nissen;E. Murat Tuzcu;Paul Schoenhagen;Tim Crowe.
The New England Journal of Medicine (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: